WO2000070079A1 - High throughput assay for modulators of nuclear receptors - Google Patents
High throughput assay for modulators of nuclear receptors Download PDFInfo
- Publication number
- WO2000070079A1 WO2000070079A1 PCT/US2000/012863 US0012863W WO0070079A1 WO 2000070079 A1 WO2000070079 A1 WO 2000070079A1 US 0012863 W US0012863 W US 0012863W WO 0070079 A1 WO0070079 A1 WO 0070079A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- receptor
- antibody
- estrogen receptor
- estrogen
- protein
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Definitions
- nuclear receptors are natural receptors for small lipophilic molecules, they are attractive therapeutic targets for the pharmaceutical industry, yielding some of the most important pharmaceuticals available, including oral contraceptives, anti-cancer drugs, anti-asthmatic compounds, anti-diabetic compounds and skin treatments. Given the intense interest in these therapeutic areas, these receptors will likely be active pharmaceutical targets for the foreseeable future.
- the size of the nuclear receptor superfamily has greatly expanded, so that there are at least 50 known mammalian members, the majority of which lack a known ligand. It is likely that, as ligands for these so-called orphan receptors are identified, many will represent equally fruitful drug targets.
- a robust, automated screening protocol will be required for screening compounds against this family of receptors.
- Emission of visible light forms the basis of detection of successful ligand/target interaction, and is measured by an appropriate monitoring device.
- An example of a scintillation proximity assay is disclosed in United States Patent No. 4,568,649, issued February 4, 1986.
- US patent 5,770,176 describes assays for nuclear receptors wherein the functional receptor binds to immobilized nucleic acid. Materials for these types of assays are commercially available from DuPont NEN® (Boston, Massachusetts) under the trade name FlashPlateTM. This methodology has been applied to membrane proteins, transcription factors and antibodies. Recently, it has also been applied to nuclear receptors (Haggblad, J., Carlsson, B., Kivela, P. and Siitari, H. (1995).
- the present invention provides a high throughput method to detect ligands that bind to full-length or fragmented nuclear receptor proteins.
- the method of the invention is a robust, sensitive, non-perturbing assay.
- the present invention provides an assay of simple design such that it is easily automated and an assay design that can be easily modified to allow different nuclear receptor targets to be tested without significant modification of the design.
- the present invention relates to a scintillation proximity method to screen compounds that bind to nuclear receptor proteins by using displacement of an established radiolabeled ligand.
- a solution containing two ligands, one sample ligand and a radiolabeled ligand are incubated with immobilized nuclear receptor protein for sufficient time to allow binding equilibrium to be achieved.
- the bound radiolabel is measured indirectly by monitoring the fluorescence of the immobilized support carrying the nuclear receptor protein. Therefore, measuring reduced fluorescence of a vessel containing a sample, the radiolabeled ligand, and the nuclear receptor compared to a vessel containing only radiolabeled ligand and nuclear receptor would indicate that the sample was specifically bound to the nuclear receptor protein.
- the estrogen receptor exists in two forms, ⁇ and ⁇ , and is a target for preventing osteoporosis and other post- menopausal conditions, and for treating breast cancer.
- the methods described herein can easily be adapted for use with other nuclear receptors where at least one ligand is known.
- Figure 1 Establishment of a homogeneous competitive binding assay for estrogen receptor ⁇ ligands using antibody capture of the receptor.
- Estrogen receptor ⁇ (0.75 or 10 pmol) was added in triplicate to the wells of 96 well FlashPlates previously coated with goat anti-mouse immunoglobulin.
- SRA-1010 anti-estrogen receptor ⁇ antibody (0.5 ⁇ g) was added or omitted as shown. The plates were incubated at approximately 4°C for three days. Then, excess protein was removed by washing the plates.
- Figure 7 Use of a polyclonal antibody to generate a homogeneous competitive binding assay for ligands binding to estrogen receptor ⁇ .
- Estrogen receptor ⁇ (1.7 pmol) and different amounts of anti-estrogen receptor] ⁇ antibody PA 1-313 were added in duplicate to the wells of a 96 well FlashPlate previously coated with sheep anti-rabbit immunoglobulin, and incubated at approximately 4°C overnight. The next day, excess protein was removed by washing the plate.
- estradiol and either 500 nM 17 ⁇ -estradiol ("+ competitor") or the solvent vehicle (0.75% [v/v] dimethyl sulfoxide; "w/o competitor”), were added and incubated for one hour at ambient temperature prior to measurement using a TopCount scintillation counter.
- FIG. 8 Flow diagram of the binding assay.
- the assay of the present invention is shown using antibody capture as the affinity capture.
- protein domain refers to a region of a protein that can fold into a stable three-dimensional structure independently of the rest of the protein.
- This structure may maintain a specific function associated with the domain's function within the intact protein, including enzymatic activity, creation of a recognition motif for another molecule, or provision of the necessary structural components for a protein to exist in a particular environment.
- Protein domains are usually evolutionarily conserved regions of proteins, both within a protein family and within other protein superfamilies that require similar functions.
- protein superfamily refers to proteins whose evolutionary relationship may not be entirely established or that may be distant by accepted phylogenetic standards, but that show a similar three-dimensional structure or display unique consensus critical amino acids.
- fusion protein refers to a protein construct that is the result of combining multiple protein domains or linker regions for the purpose of gaining function of the combined functions of the domains or linker regions. This is most often accomplished by molecular cloning of the nucleotide sequences to result in the creation of a new polynucleotide sequence that codes for the desired protein. Alternatively, creation of a fusion protein may be accomplished by chemically joining two proteins together.
- linker region refers to stretches of polynucleotide or polypeptide sequence that are used in the construction of a cloning vector or fusion protein. Functions of a linker region can include introduction of cloning sites into the nucleotide sequence, introduction of a flexible component or space-creating region between two protein domains, or creation of an affinity tag for specific molecular interaction. A linker region may be introduced into a fusion protein without a specific purpose, but as a compromise that results from choices made during cloning.
- cloning site or “polycloning site” as used herein refers to a region of the nucleotide sequence contained within a cloning vector or engineered within a fusion protein that has one or more available restriction endonuclease consensus sequences.
- the use of a correctly chosen restriction endonuclease results in the ability to isolate a desired nucleotide sequence that codes for an in-frame sequence relative to a start codon that yields a desirable protein product after transcription and translation.
- These nucleotide sequences can then be introduced into other cloning vectors, used to create novel fusion proteins, or used to introduce specific site-directed mutations.
- expression vectors are defined as DNA sequences that are required for the transcription of cloned copies of genes and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic or prokaryotic genes in a variety of hosts including Escherichia coli, blue-green algae, plant cells, insect cells, fungal cells including yeast cells, and animal cells.
- a “functional derivative” of the estrogen receptor is a construct that possesses a biological activity, either functional or structural, that is substantially similar to the properties described herein.
- the term “functional derivative” is intended to include the “fragments,” “variants,” “degenerate variants,” “analogs” and “homologues” of the construct presented.
- fragment is meant to refer to any nucleic acid or polypeptide subset of the modules described herein.
- variant is meant to refer to a construct or coding sequence module substantially similar in structure and function to either the entire estrogen receptor molecule or to a fragment thereof.
- a construct is "substantially similar" to the estrogen receptor construct if both molecules have similar structural characteristics or if both molecules possess similar biological properties ie, can be manipulated such that they express recombinant estrogen receptor. Therefore, if the two molecules possess substantially similar activity, they are considered to be variants even if the structure of one of the molecules is not found in the other or even if the two amino acid sequences are not identical.
- the term “analog” refers to a molecule substantially similar in function to either the entire estrogen receptor molecule or to a fragment thereof.
- sample as used herein in connection with a ligand for a nuclear receptor protein refers to an organic or inorganic molecule that has the potential to disrupt the specific binding of a known ligand for the receptor.
- samples may include small organic or inorganic molecules, synthetic or natural amino acid peptides, proteins, or synthetic or natural nucleic acid sequences, or any chemical derivatives of the aforementioned.
- chemical derivative describes a molecule that contains additional chemical moieties that are not normally a part of the base molecule. Such moieties may improve the solubility, half-life, absorption, etc. of the base molecule. Alternatively the moieties may attenuate undesirable side effects of the base molecule or decrease the toxicity of the base molecule. Examples of such moieties are described in a variety of texts, such as Remington's Pharmaceutical Sciences.
- radiolabeled ligand as used herein in connection with displacement assays is a ligand known to bind to a known nuclear receptor, which is capable of being made radioactive.
- the types of radioactive tracers used to label the ligand include any of the known ⁇ -particle emitters or Auger electrons, including [ 3 H], [ 14 C], [ 35 S], [ 33 P], [ 32 P], [ 125 I], and [ 131 I], with [ 3 H] being generally preferred due to its relative safety.
- the concentration of radiolabeled ligand used is closely matched to the natural ligand' s affinity (Kd) for its receptor. Most natural ligands for nuclear receptors have Kd's below 10 nanomolar.
- Radiolabeled nuclear receptor ligands are available from a number of commercial sources, including NEN Life Sciences and Amersham. Labeled ligands are available for the estrogen, progesterone, androgen, glucocorticoid, vitamin D, thyroid hormone and retinoic acid receptors.
- receptor refers to members of the nuclear receptor family or superfamily.
- Sources of receptor for use in the invention can include tissue or cell extracts, or purified receptor derived from natural or recombinant sources expressed in E. coli, yeast, insect or mammalian cells, or other cell source, with purified, recombinant receptor being generally preferred. Crude tissue or cell extracts, or partially purified extracts, may also be appropriate, provided that the receptor is expressed at at least approximately 5 micromolar concentration in the extract. It is well known by those in the art that different receptors from different animal species may bind the same ligands, and this invention extends to all sources of nuclear receptors where binding of the mammalian ligand can be shown.
- high throughput refers to an assay design that allows easy analysis of multiple samples simultaneously, capacity for robotic manipulation, and small sample volume.
- assay formats include 96-well or 384-well plates used for liquid handling experiments. It is well known by those in the art that as miniaturization of plastic molds and liquid handling devices is advanced, or as improved assay devices are designed, greater numbers of samples may be analyzed using the design of the present invention. Use of 96-well plate assays in the examples is given for illustrative purposes only.
- the present invention provides a high throughput method to detect ligands that bind to full-length or fragmented nuclear receptor proteins that is of simple design such that it is easily automated and can be easily modified to allow different nuclear receptor targets to be tested without significant modification.
- the present invention relates to a scintillation proximity method to screen compounds that bind to nuclear receptor proteins by using displacement of an established radiolabeled ligand.
- a solution containing two ligands, one sample ligand and a radiolabeled ligand are incubated with immobilized nuclear receptor protein for sufficient time to allow binding equilibrium to be achieved. Afterwards, the bound radiolabel is measured indirectly by monitoring the fluorescence of the immobilized support carrying the nuclear receptor protein.
- the present invention provides use of any scintillant-impregnated or coated high throughput vessel, with multiple well plates (96 well, 384 well etc.) being generally preferred.
- Uncoated scintillant-containing plates can be purchased from Packard or NEN Life Sciences.
- the plates can also be purchased pre-coated with an anti-species antibody (depending on the antibody to be used), or anti-species antibody can be pre-coated to a basic plate by the user prior to incubation with receptor and anti-receptor antibody.
- plates can be purchased pre-coated with streptavidin, or appropriate capture material (anti-Flag antibody, anti- glutathione S-transferase antibody, etc.) can be pre-coated to plates prior to incubation with the tagged protein.
- capture material anti-Flag antibody, anti- glutathione S-transferase antibody, etc.
- Histidine tagged fusion proteins one could use a scintillation proximity vehicle coated with a nickel surface.
- Pre- coating of antibodies can be performed by overnight incubation at 4 °C in appropriate buffers, using plates containing anti-species antibody or treated with, for example, poly-lysine.
- a scintillation proximity assay requires efficient immobilization of the protein of interest to the scintillant-containing surface. Binding of whole estrogen receptor can be achieved by simple adsorption, but this does not usually yield a stably bound protein. While larger amounts of receptor would increase the sensitivity of the reaction, this would create a greater requirement for purified receptor, and thus make the method less cost-effective.
- the protein target can be immobilized to the surface using an intermediate affinity capture motif.
- Methods of affinity capture include but are not limited to: biotin/avidin technology, directed fusion protein interactions such as between glutathione and glutathione S-transferase or dextran and maltose binding domain, and antibodies directed against the protein itself or a fragment thereof, or against a fusion tag contained in a fusion protein.
- the type of antibody used to establish an assay of this type may be either monoclonal (recognizing one epitope of its target protein) or polyclonal (recognizing multiple epitopes).
- the optimal antibody for a given receptor can be determined experimentally, because some antibodies may yield greater signal-to-noise ratios than others, depending on the epitope or epitopes of the receptor that each recognizes.
- Monoclonal and polyclonal antibodies against nuclear receptors are available from a number of commercial sources (Affinity BioReagents, Stressgen, Transduction
- Custom antibodies can be generated by the user according to standard procedures (immunization of rabbits or mice with pure protein or peptide). The amount of antibody to be used per well will depend primarily on its avidity for the receptor or receptor fragment, and is well known by those in the art. Likewise, the positions of engineered affinity tags should be chosen so as not to disrupt ligand binding. However, for nuclear receptors in general, use of an epitope outside the ligand binding domain, or positioning of a tag amino-terminal of the ligand binding domain, is unlikely to lead to disruption.
- the present invention allows use of any buffer that maintains an appropriate pH and salt concentration to allow receptor binding to the plate and for incubation of the receptor with the ligands.
- the present invention allows buffer additives that enhance stability of a particular protein, and these conditions are well known by those in the art.
- the estrogen receptor ⁇ which is a relatively unstable protein, uses high concentrations of dithiothreitol in a complex buffer, commercially available from Panvera.
- the estrogen receptor ⁇ which is more stable, uses a simpler buffered salt solution, also commercially available from Panvera.
- Compounds identified according to the methods disclosed herein may be used alone at appropriate dosages defined by routine testing in order to obtain optimal inhibition of the binding of test ligand to the receptor, or modulation of its activity, while minimizing any potential toxicity.
- co-administration or sequential administration of other agents may be desirable.
- Sources of receptor The examples taught herein use purified estrogen receptor ⁇ or ⁇ from Panvera (Madison, WI, USA). The human estrogen receptor ⁇ is expressed in baculovirus-infected insect cells and subsequently purified to greater than 95%> purity by the manufacturer. Estrogen receptor ⁇ is expressed and purified in a similar way. For all methods described herein, approximately 50 ng (0.75 pmol) of purified estrogen receptor ⁇ were added to each well. Approximately 100 ng (1.7 pmol) of estrogen receptor ⁇ were added to each well.
- Anti-estrogen receptor ⁇ mouse monoclonal antibodies tested were obtained as follows: MA1-310 from Affinity BioReagents (Golden, CO, USA), E51320 from Transduction Laboratories (Lexington, KY, USA), SRA-1000 and SRA-1010 from Stressgen Biotechnologies (Victoria, BC, Canada).
- the anti-estrogen ⁇ rabbit polyclonal antibody PA 1-313 was obtained Affinity BioReagents (Golden, CO, USA).
- Radiolabeled 16 -[ 125 I]-iodo-3, 17 ⁇ - estradiol and [2,4,6,7,16, 17- 3 H(N)] -estradiol were both obtained from NEN Life Science Products.
- streptavidin-coated plates could be used to capture a biotinylated receptor or receptor fragment.
- Basic plates are available from NEN and Packard.
- Estrogen Screening Buffer (Panvera) was used for estrogen receptor ⁇ incubations. Dithiothreitol was added to 5 mM prior to use.
- BGG buffer (Panvera) was used for estrogen receptor ⁇ incubations. All washes were performed in phosphate-buffered saline, pH 7.2.
- the receptor-ligand complex appears to be remarkably stable. After the tracer was added, specific counts dropped slightly after four hours of incubation at room temperature, but the signal-to-background ratio was still over four-fold after 18 hr of incubation ( Figure 3). However, sufficient time is required to form the antibody-receptor complex ( Figure 4). Total counts are barely above control when the receptor was added with the tracer instead of with the antibody the previous evening.
- Estrogen receptor ⁇ add 100 ⁇ L Estrogen Screening Buffer containing 5 mM dithiothreitol, 0.5 ⁇ g mouse anti-estrogen receptor ⁇ antibody SRA-1010 and 50 ng (0.75 pmol) purified human estrogen receptor ⁇ to each well of a 96 well FlashPlate Plus plate cross-linked with goat anti-mouse antibodies.
- Estrogen receptor ⁇ add 100 ⁇ L Estrogen Screening Buffer or BGG Buffer containing 2.0 ⁇ g rabbit anti-estrogen receptor ⁇ antibody PA1-313 and 100 ng (1.7 pmol) purified human estrogen receptor ⁇ to each well of a 96 well FlashPlate Plus plate cross-linked with sheep anti-rabbit antibodies.
- CV's coefficients of variation across duplicate plates were determined on two separate days, for each assay (Table 1). CV's were 10%> or less for both the estrogen receptor ⁇ and the estrogen receptor ⁇ assays when they were performed in the presence of the appropriate antibody. With the amounts of receptor used, CV's were higher (14% > to over 20%) in the absence of the antibodies. Within an experiment, variability was 1.5 to over three times higher in the absence of antibody compared to in its presence. Presumably, this was due to the lower total counts obtained in the absence of the antibodies.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU48385/00A AU4838500A (en) | 1999-05-13 | 2000-05-10 | High throughput assay for modulators of nuclear receptors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31179799A | 1999-05-13 | 1999-05-13 | |
US09/311,797 | 1999-05-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000070079A1 true WO2000070079A1 (en) | 2000-11-23 |
WO2000070079A8 WO2000070079A8 (en) | 2001-02-08 |
Family
ID=23208519
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/012863 WO2000070079A1 (en) | 1999-05-13 | 2000-05-10 | High throughput assay for modulators of nuclear receptors |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR023985A1 (en) |
AU (1) | AU4838500A (en) |
WO (1) | WO2000070079A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003006988A1 (en) * | 2001-07-13 | 2003-01-23 | Janssen Pharmaceutica N.V. | Cardiovascular safety assay |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US5389517A (en) * | 1989-07-31 | 1995-02-14 | Trustees Of Boston University | Specific antibodies against the DNA-binding domain of and immunoassays to determine the presence and functional status of estrogen receptor proteins |
US5512429A (en) * | 1989-09-19 | 1996-04-30 | British Technology Group Limited | Assay for enzyme activity |
US5783398A (en) * | 1995-09-15 | 1998-07-21 | Merck & Co., Inc. | High throughput assay using fusion proteins |
-
2000
- 2000-05-10 AU AU48385/00A patent/AU4838500A/en not_active Abandoned
- 2000-05-10 WO PCT/US2000/012863 patent/WO2000070079A1/en active Application Filing
- 2000-05-15 AR ARP000102324 patent/AR023985A1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4568649A (en) * | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
US5389517A (en) * | 1989-07-31 | 1995-02-14 | Trustees Of Boston University | Specific antibodies against the DNA-binding domain of and immunoassays to determine the presence and functional status of estrogen receptor proteins |
US5512429A (en) * | 1989-09-19 | 1996-04-30 | British Technology Group Limited | Assay for enzyme activity |
US5783398A (en) * | 1995-09-15 | 1998-07-21 | Merck & Co., Inc. | High throughput assay using fusion proteins |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003006988A1 (en) * | 2001-07-13 | 2003-01-23 | Janssen Pharmaceutica N.V. | Cardiovascular safety assay |
US7820453B2 (en) | 2001-07-13 | 2010-10-26 | Janssen Pharmaceutica N.V. | Cardiovascular safety assay |
Also Published As
Publication number | Publication date |
---|---|
AR023985A1 (en) | 2002-09-04 |
WO2000070079A8 (en) | 2001-02-08 |
AU4838500A (en) | 2000-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2309879C (en) | Nuclear hormone receptor drug screens | |
JP2001503131A (en) | Compositions and methods for screening pharmaceutical libraries | |
CA2305711A1 (en) | Assays for nuclear receptor ligands using fret | |
US20090022623A1 (en) | Peptides Capable of Functioning as Mimotopes for Hormonal Analytes | |
WO2000070079A1 (en) | High throughput assay for modulators of nuclear receptors | |
US6555326B1 (en) | Nuclear hormone receptor fluorescence polarization assay | |
US7348151B1 (en) | Method for the cellular high-throughput-detection of nuclear receptor ligand interactions | |
Murata et al. | Piezo Electric Sensor for Endocrine-Disrupting Chemicals Using Receptor–co-factor Interaction | |
US6579686B2 (en) | Constitutive androstane receptor | |
JP4811400B2 (en) | Method for detecting a binding substance for a nuclear receptor | |
US20060110732A1 (en) | Method for the identification of ligands | |
US20060099643A1 (en) | Method for determining the regulation of xenobiotic removal | |
Ben Abid et al. | New Phage Display-Isolated Heptapeptide Recognizing the Regulatory Carboxy-Terminal Domain of Human Tumour Protein p53 | |
WO2004010141A1 (en) | Method for the identification of ligands | |
US20080261327A1 (en) | Cell Free Assay for Determining a Substance of Interest and Molecular Complexes Used Therefore | |
Fay et al. | Purification and Analysis of by Functional Site-Directed CB1 Fluorescence Labeling Methods | |
WO2004076473A2 (en) | Androgen receptor interacting peptides | |
JP2003344411A (en) | Immobilization method of receptor, and receptor composition manufactured by the method | |
JPH11295315A (en) | Assay system of glycoprotein agonist and antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WR | Later publication of a revised version of an international search report | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
CFP | Corrected version of a pamphlet front page |
Free format text: REVISED ABSTRACT RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |